Microcap Ledger Allarity Therapeutics, Inc. $ALLR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 15,910,724 [10-Q 2026-08-14]
What the company doesAI summary of filing
Allarity Therapeutics is a clinical-stage pharmaceutical company developing stenoparib, a dual inhibitor of PARP and tankyrase enzymes, for cancer treatment. The company generates revenue through laboratory services for gene expression analysis and DRP diagnostic work, which totaled $0.3 million in 2025. Stenoparib is currently in phase 2 clinical trials for platinum-resistant or platinum-ineligible ovarian cancer and in a separate phase 2 trial combining stenoparib with temozolomide for small cell lung cancer, with the latter fully funded by the U.S. Veterans Administration. The company also develops the stenoparib-DRP companion diagnostic to identify patients most likely to benefit from the drug. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $25.0K | −$6.16M | −$7.06M | $16.98M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $320.0K | −$11.23M | −$14.82M | $14.69M | [10-K 2026-03-30] |
| FY ended Dec 2024 | $0.00 | −$24.52M | −$17.35M | $19.53M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$3.53M
- Cash runway Estimate
- ~14.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 4,433,587 | [10-Q 2024-11-14] |
| 2025-03-31 | 17,014,737 | [10-K 2025-03-31] |
| 2025-05-08 | 15,079,572 | [10-Q 2025-05-09] |
| 2025-08-14 | 14,619,636 | [10-Q 2025-08-15] |
| 2025-11-13 | 15,811,886 | [10-Q 2025-11-14] |
| 2026-03-30 | 15,818,980 | [10-K 2026-03-30] |
| 2026-05-15 | 15,910,724 | [10-Q 2026-05-15] |
| 2026-08-14 | 15,910,724 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-02-12; declared effective 2026-04-24 [S-3 2026-02-12]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-30 | Graff Jeremy R. | exercise | 39,494 | — | [4 2026-10-09] |
| 2026-09-30 | Graff Jeremy R. | other | 14,613 | $0.97 | [4 2026-10-09] |
| 2026-01-28 | Jensen Thomas | grant | 200,000 | — | [4 2026-05-14] |
| 2026-01-28 | Mclaughlin Gerald W. | grant | 45,000 | — | [4 2026-05-07] |
| 2026-01-28 | Ervin Jeffrey S | grant | 150,000 | — | [4 2026-04-30] |
| 2026-01-22 | Graff Jeremy R. | exercise | 48,147 | — | [4 2026-10-09] |
| 2026-01-22 | Graff Jeremy R. | other | 17,814 | $1.18 | [4 2026-10-09] |
| 2026-01-07 | Hoeiland Jesper | grant | 25,000 | — | [4 2026-05-11] |
| 2026-01-07 | Graff Jeremy R. | grant | 133,333 | — | [4 2026-01-16] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-01 | 8-K | Other events |
| 2026-09-29 | 8-K | Other events |
| 2026-09-16 | 8-K | Other events |
| 2026-09-14 | 8-K | Other events |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-01 | 8-K | Shareholder vote results; Other events |
| 2026-06-22 | 8-K | Other events |
| 2026-06-02 | 8-K | Director or officer change |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-08 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-06 | 8-K | Other events |
Alerts for $ALLR
Email me when Allarity Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.